Ataraxis Breast
The first clinically validated AI-native prognostic/predictive platform for invasive breast cancer. Ataraxis Breast uses multi-modal patient data, including pathology slides from standard biopsy and surgery specimens, to predict patient outcomes and help personalize treatment decisions in all breast cancer subtypes.
Using Ataraxis Breast
For All Breast Cancer Subtypes
More Accurate than Genomics
1-Day Turnaround
No Tissue Exhausted
Development & Clinical Validation
Robust development and validation data
Ataraxis Breast RISK score was developed and validated using data from 8,161 breast cancer patients treated at 15 institutions in 7 countries.
The study included patients with all subtypes of early-stage and locally advanced invasive breast cancer, marking this as one of the most comprehensive evaluations of a prognostic/predictive test.
Over 50% improvement in accuracy compared to standard of care genomic tests
In validation of the Ataraxis Breast RISK score on three external cohorts from top international cancer centers, Ataraxis Breast reduced prediction error by approximately 50% compared to the standard of care genomic assays for hormone receptor-positive invasive breast cancer.
Works in all clinically relevant invasive breast cancer subgroups
Ataraxis Breast RISK was developed and validated on robust and diverse data from seven countries. The data included previously underserved groups, such as triple-negative breast cancer patients. Ataraxis Breast RISK was shown to be consistently prognostic across groups with various age, race, molecular and histological subtype, and nodal status.
View a Sample Report
Explore our sample report and learn more about how predictions made by Ataraxis Breast RISK can help in recurrence risk assessment and making more personalized decisions about treatment.
Frequently Asked Questions
Testing is performed by Ataraxis AI, located at 230 Sunport Lane Ste 100, Orlando, FL 32809. Ataraxis Breast RISK was developed and its performance characteristics were determined by Ataraxis AI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Ataraxis Breast is intended to help physicians assess the risk of breast cancer recurrence, death, and therapeutic benefit for patients diagnosed with invasive breast cancer.
The total out-of-pocket cost will be based on the patient's insurance plan. We are committed to providing patients access to Ataraxis Breast as soon as possible and regardless of their financial situation.
We deliver results within one business day of receiving the specimen.
You can order Ataraxis Breast RISK and other tests through Ataraxis Ordering Portal. If you don't yet have an account with Ataraxis, please contact us.
No, Ataraxis Breast does not require any additional procedures as it uses existing biopsy or resection specimens.